Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II dose-ranging trial of MK-5172 with peginterferon alfa-2b and ribavirin in treatment-naive chronic hepatitis C
2012-003333-42Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Oct 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of grazoprevir in chronic hepatitis C (CHC), sponsored by Merck & Co.. Started Oct 2012; status: completed.
02
Drugs
grazoprevir
03
Conditions
chronic hepatitis C (CHC)
Beyond the preview
Go deeper on 2012-003333-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-003333-42.